Antibiotice Iasi (stock symbol: ATB), the largest Romanian owned drug maker, ended the first quarter of 2026 with net profit of RON12.5 million, down 61.5% on the year, amid the contraction of the domestic generic medicines market and fiscal measures applied since the start of 2026, per the company's financial report.